Cytena

Cytena

Cytena develops single-cell printing technology for cell research and professional diagnostics. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
AUD51m (Public information from Aug 2019)
Company register number HRB 711600 (Freiburg im Breisgau)
Freiburg Baden-Württemberg (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR201620172018201920202021
Revenues--<1m--10.0m
Profit<1m<1m<1m<1m(<1m)(2.6m)
% profit margin--24 %--(26 %)

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
N/A

€1.1m

Seed

N/A

-

€480k

Grant
*

€3.0m

Series A

€30.3m

Valuation: €30.3m

50.4x EV/LTM Revenues

Acquisition
Total FundingAUD7.8m

Recent News about Cytena

Edit
More about Cytenainfo icon
Edit

Cytena specializes in single cell dispensing technology, which significantly enhances cell line development, single cell omics, and microbiome workflows. The company operates in the biotechnology sector, serving clients such as pharmaceutical companies, research institutions, and biotech firms. Cytena's business model revolves around providing advanced instruments and solutions that ensure efficiency, accuracy, and proof of clonality in single cell applications. The company generates revenue through the sale of its patented dispensing instruments, as well as offering online demos, trainings, and workflow consultations. By leveraging automation and microtechnology, Cytena aims to empower its customers to achieve better results faster, ultimately improving patient care.

Keywords: single cell dispensing, cell line development, single cell omics, microbiome workflows, biotechnology, automation, microtechnology, pharmaceutical, research institutions, biotech firms.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.